Skip to main content
HCPCS J2792 · Level II · Part B drug

J2792: rho d immune globulin (Winrho SDF), HCPCS Level II J code

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: ASP payment limits: October 2026 (effective October 1, 2026); NCCI MUE tables: 2026 Q4 (effective October 1, 2026); NCCI PTP edits: v323r0 (2026 Q4) (effective October 1, 2026); OPPS Addendum B: October 2026 (effective October 1, 2026); ASC Addendum BB (covered ancillary services): October 2026 (effective October 1, 2026). Next CMS release: January 1, 2027 (quarterly update).

Key facts for J2792

Billing unit
100 IU
Rho(d) immune globulin h, sd
ASP payment limit
$35.395
October 2026; -1.1% vs July 2026
Practitioner MUE
450
MAI 3
OPPS status
SI K
APC 1609
NCCI exposure
1 col-2 pairs
100% allow a modifier
Coverage articles
2
6 states

TL;DR

HCPCS J2792 is the Level II code for Injection, rho d immune globulin, intravenous, human, solvent detergent, 100 iu, billed per 100 IU. The Medicare Part B ASP payment limit for October 2026 is $35.395 per billing unit, down 1.1% from July 2026. The practitioner MUE allows up to 450 units per date of service (MAI 3), so a full 450-unit day is $15,927.75 at the current limit. Under OPPS it carries status indicator K in APC 1609. J2792 is billed in units of 100 IU; the quantity administered, the NDC package and the units on the claim must reconcile, which is the check that prevents CARC 16 and 151 returns on this line. Other HCPCS codes whose descriptor names rho d immune globulin: J2790 (CMS descriptor names "full dose"; billed per 300 mcg (1500 IU)); J2788 (HyperRho S/D from Grifols USA, LLC; billed per 50 mcg (250 IU)). The ASP crosswalk maps 6 NDCs to it, sold as Winrho SDF by Kamada Ltd. It is the bundled column-2 code in 1 NCCI pair, most often with J2790. 2 Medicare coverage articles list the code across 6 states, including A56718.

Medicare Part B payment limit (ASP)

CMS sets the Part B payment limit for J2792 at $35.395 per 100 IU for October 2026, derived from manufacturer average sales price plus 6%, compared with $35.791 in July 2026. Beneficiary coinsurance is 20%.

ASP payment limits for J2792
QuarterPayment limitPerCoinsurance
October 2026$35.395100 IU20%
July 2026$35.791100 IU—
Source: CMS Medicare Part B Drug Payment Limit File. Commercial and Medicaid payers set their own rates.

NDC to HCPCS billing-unit conversion

The October 2026 ASP crosswalk maps 6 NDCs from 1 labeler to J2792. Report the NDC in the claim's drug segment and bill the number of J2792 units that equals the quantity administered divided by 100 IU; the last column gives units per full package.

NDCs that crosswalk to J2792
NDCDrug nameLabelerPackage sizeBilling units / package
49591-0300-51Winrho SDFKamada Ltd.13 × 1150
49591-0330-51Winrho SDFKamada Ltd.1.3 × 115
49591-0350-51Winrho SDFKamada Ltd.2.2 × 125
70257-0310-51Winrho SDFKamada Ltd.4.4 × 150
70257-0330-51Winrho SDFKamada Ltd.1.3 × 115
70257-0350-51Winrho SDFKamada Ltd.2.2 × 125

Medically Unlikely Edits (MUE)

CMS publishes 3 MUE values for J2792. For practitioners the limit is 450 units per date of service with adjudication indicator 3, a date-of-service clinical edit: units above the limit deny but can be paid on appeal with documentation that the quantity was medically reasonable.

MUE values for J2792 by setting
SettingMUE (units/DOS)MAICMS rationale
Practitioner services4503 Date of Service Edit: ClinicalPrescribing Information
Facility outpatient hospital4503 Date of Service Edit: ClinicalPrescribing Information
DME supplier03 Date of Service Edit: ClinicalCMS Policy

MUE for J2792 in every setting opens the lookup with this code filled in, next to any other code on the same claim.

NCCI edits and add-on relationships

In the practitioner PTP file v323r0 (effective October 1, 2026), J2792 is the column-2 code in 1 active pair, 100% of which allow a modifier (indicator 1), and the column-1 code in 1. 1 historical pair have been deleted over time. CMS's most frequent rationale: Mutually exclusive procedures.

When billed with these column-1 codes, J2792 is the bundled component unless the pair allows a modifier and the documentation supports a distinct service.

Column-1 codes most often paired with J2792
Column-1 codePairs
J2790 Rho d immune globulin inj1

These codes are considered components of J2792 when reported together on the same date of service.

Column-2 codes most often bundled into J2792
Column-2 codePairs
90385 (CPT; descriptor licensed by AMA)1

The counts above are exposure, not answers for a specific claim. Check J2792 against another code to see whether a given pair bundles, which code is paid and whether a modifier can separate them.

J2792 is neither an add-on code nor a designated primary code in the 2026 Q4 NCCI add-on edit file.

Medicare coverage articles

2 current Medicare Administrative Contractor articles list J2792 in their HCPCS tables, covering 6 states. Each article carries the covered and non-covered ICD-10 codes that medical-necessity denials (CARC 50) are adjudicated against.

Billing and Coding Articles listing J2792
ArticleTitleContractor(s)StatesRelated LCD
A56718Billing and Coding: Intravenous Immunoglobulin (IVIG)Palmetto GBANC SC VA WVL34580
A57160Billing and Coding: Immune Thrombocytopenia (ITP) TherapyCGS Administrators, LLCKY OHL38268

Diagnoses Medicare contractors cover for J2792

2 billing and coding articles attach a covered diagnosis list to J2792: 212 distinct ICD-10-CM codes in all. The 15 below come first by how many of those articles cover them, then in the contractor's own order. The claim line is checked against the list of the contractor that processes it, and a diagnosis outside that list is denied as not medically necessary (CARC 50).

First 15 covered ICD-10-CM codes for J2792
ICD-10-CMDescription (FY2027)Articles covering
D69.3Immune thrombocytopenic purpura2 of 2
A85.8Other specified viral encephalitis1 of 2
B08.3Erythema infectiosum [fifth disease]1 of 2
B20Human immunodeficiency virus [HIV] disease1 of 2
B25.0Cytomegaloviral pneumonitis1 of 2
B25.1Cytomegaloviral hepatitis1 of 2
B25.2Cytomegaloviral pancreatitis1 of 2
B25.8Other cytomegaloviral diseases1 of 2
B25.9Cytomegaloviral disease, unspecified1 of 2
C88.00Waldenstrom macroglobulinemia not having achieved remission1 of 2
C90.00Multiple myeloma not having achieved remission1 of 2
C90.02Multiple myeloma in relapse1 of 2
C91.10Chronic lymphocytic leukemia of B-cell type not having achieved remission1 of 2
C91.11Chronic lymphocytic leukemia of B-cell type in remission1 of 2
C91.12Chronic lymphocytic leukemia of B-cell type in relapse1 of 2
197 more codes are in the full lists linked below.

Contractors split an article's diagnoses into numbered groups and say in each group's instructions which procedure codes it supports. Only the groups that apply to J2792 are counted here. The full list opens on the policy page with every group, the non-covered codes and the instructions.

Covered diagnosis lists that apply to J2792, by article
ArticleContractorGroups that applyCovered codes for J2792Full list
A56718Palmetto GBAone list for every code in the article212On LCD L34580
A57160CGS Administrators, LLCone list for every code in the article1On LCD L38268

Local coverage policies that list J2792

2 active Local Coverage Determinations list J2792 in the policy or in its billing and coding article. Each applies only in its contractor's jurisdiction; check the one for the state where the drug is administered.

Hospital outpatient (OPPS) status

In the October 2026 OPPS Addendum B, J2792 carries status indicator K and is assigned to APC 1609, with a published national unadjusted payment of $35.395. Status K means the drug is paid separately under OPPS at the ASP-based rate rather than packaged into the procedure.

Ambulatory surgical center (ASC) payment

In the October 2026 ASC Addendum BB (covered ancillary services), J2792 carries payment indicator K2, which CMS defines as "Drugs, biologicals, and radiopharmaceuticals paid separately when provided integral to a surgical procedure on ASC list; payment based on OPPS rate". The national ASC payment is $35.40 per 100 IU, paid only when the drug is furnished integral to a covered surgical procedure.

Common denials for J2792 and how to prevent them

NDC missing, invalid or not matched to the HCPCS code

units billed exceed the MUE for the date of service

diagnosis not covered by the applicable coverage article or LCD

For teams evaluating QuickIntell software

Evaluate a coding workflow for J2792

Use the unit, NDC and edit questions in this reference to scope a QuickCode evaluation for qualified coder review, documentation clarification and the billing handoff. Confirm supported code sets, data inputs and reviewer responsibilities; the reference tables do not establish that a particular automated check or payer integration is available.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions — HCPCS J2792

What does HCPCS code J2792 describe?

J2792 is defined by CMS as "Injection, rho d immune globulin, intravenous, human, solvent detergent, 100 iu". Each billing unit represents 100 IU, so the units reported on the claim must equal the dose administered divided by that unit.

Is J2792 a CPT code?

No. J2792 is a HCPCS Level II code, the letter-plus-four-digit set CMS maintains for drugs such as rho d immune globulin (Winrho SDF); CPT codes are five-character codes maintained by the AMA. On a Part B claim J2792 reports the drug itself in 100 IU units, and the administration is billed on its own line.

What is the Medicare reimbursement for J2792 in October 2026?

The ASP-based payment limit is $35.395 per 100 IU, with 20% beneficiary coinsurance. The July 2026 limit was $35.791. Commercial payers use their own fee schedules.

How many units of J2792 can be billed per day?

The practitioner Medically Unlikely Edit is 450 units per date of service with adjudication indicator 3 (Date of Service Edit: Clinical). MAI 3 edits can be appealed with documentation that the units were medically reasonable. CMS cites "Prescribing Information" as the rationale.

Which NDCs map to J2792?

The October 2026 ASP crosswalk lists 6 NDCs from 1 labeler: Winrho SDF (Kamada Ltd.). For example NDC 49591-0300-51 (package size 13) equals 150 billing units of J2792.

Does J2792 have NCCI bundling edits?

In the v323r0 practitioner PTP file, J2792 appears as the column-2 (bundled) code in 1 active pairs and as the column-1 code in 1. 100% of the column-2 pairs allow a modifier (indicator 1). The most frequent column-1 partners are J2790, and CMS's leading rationale is "Mutually exclusive procedures".

J2792 vs J2790: what is the difference?

Both are HCPCS Level II codes whose descriptor names rho d immune globulin. What sets J2790 apart: CMS descriptor names "full dose"; billed per 300 mcg (1500 IU). J2792 is billed per 100 iu, limit $35.395, MUE 450; J2790 is billed per 300 mcg (1500 iu), limit $82.081, MUE 1. Report the code whose descriptor matches the product and setting in the record.

J2792 vs J2788: what is the difference?

Both are HCPCS Level II codes whose descriptor names rho d immune globulin. What sets J2788 apart: HyperRho S/D from Grifols USA, LLC; billed per 50 mcg (250 IU). J2792 is billed per 100 iu, limit $35.395, MUE 450; J2788 is billed per 50 mcg (250 iu), limit $27.653, MUE 1. Report the code whose descriptor matches the product and setting in the record.

Which Medicare coverage articles mention J2792?

2 current Billing and Coding Articles in the Medicare Coverage Database list J2792, covering 6 states: A56718 (Billing and Coding: Intravenous Immunoglobulin (IVIG)); A57160 (Billing and Coding: Immune Thrombocytopenia (ITP) Therapy).

What diagnosis codes support J2792?

2 Medicare billing and coding articles list 212 covered ICD-10-CM codes for J2792 between them, for example D69.3 (Immune thrombocytopenic purpura); A85.8 (Other specified viral encephalitis); B08.3 (Erythema infectiosum [fifth disease]); B20 (Human immunodeficiency virus [HIV] disease); B25.0 (Cytomegaloviral pneumonitis). Each contractor's list applies only in its own jurisdiction, so the claim must carry a code from the article of the contractor that processes it.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

This page is an operational reference compiled from CMS publications: the Medicare Part B drug payment limit and NDC crosswalk files, NCCI MUE and add-on edit tables, aggregate PTP statistics, OPPS Addendum B, ASC Addendum BB and the Medicare Coverage Database. Payment limits and rates are Medicare national amounts; commercial and Medicaid payers differ. CPT codes are shown as numbers only; CPT descriptors are copyright AMA. Nothing here is legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.